Grufity logoGrufity logo

ENOV

Market Closed

Enovis CORP

ENOV Alerts

ENOV Stock Price

RSI Chart

Valuation

Profitability

Fundamentals

Price Action

Financial Health

Investor Care

Risks

What is the probability of a big loss on ENOV?

81.9%


Probability that Enovis stock will be more than 20% underwater in next one year

55%


Probability that Enovis stock will be more than 30% underwater in next one year.

36.5%


Probability that Enovis stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ENOV drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Enovis was unfortunately bought at previous high price.

Returns

Cumulative Returns on ENOV

Which funds bought or sold ENOV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
Capital Impact Advisors, LLC
UNCHANGED
-
-1,000
482,000
0.48%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
252,000
252,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.66
-611,000
2,854,000
-%
2022-11-17
M&T Bank Corp
ADDED
20.22
560,000
697,000
-%
2022-11-17
CENTRAL TRUST Co
SOLD OFF
-100
-
-
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-140,000
-
-%
2022-11-16
Retirement Systems of Alabama
ADDED
0.7
-533,000
2,873,000
0.01%
2022-11-15
STATE STREET CORP
ADDED
7.39
-7,330,000
65,605,000
-%
2022-11-15
Almanack Investment Partners, LLC.
NEW
-
1,000
1,000
-%
2022-11-15
COOKE & BIELER LP
REDUCED
-1.46
-15,061,000
71,213,000
0.76%

1–10 of 47

Latest Funds Activity

Are funds buying ENOV calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own ENOV

Enovis News

Simply Wall St

The past year for Enovis (NYSE:ENOV) investors has not been profitable.24 hours ago

Thehour.com

ENOV Fair Value

Recent SEC filings of Enovis

View All Filings
Date Filed Form Type Document
Nov 18, 2022
4
Insider Trading
Nov 18, 2022
8-K
Current Report
Nov 17, 2022
4
Insider Trading
Nov 02, 2022
10-Q
Quarterly Report
Nov 02, 2022
8-K
Current Report
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading
Sep 20, 2022
SC 13G/A
Major Ownership Report
Aug 24, 2022
8-K
Current Report

Latest Insider Trading transactions for ENOV

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-15
PRYOR DANIEL A
ACQUIRED
3,037,990
45.06
67,421
EVP, Strategy & Business Dev.
2022-11-15
PRYOR DANIEL A
SOLD
-3,679,570
54.576
-67,421
EVP, Strategy & Business Dev.
2022-08-08
Tandy Bradley J
SOLD
-195,898
58.39
-3,355
SVP, General Counsel
2022-08-05
KLECKNER JOHN
ACQUIRED
-
-
815
Principal Accounting Officer
2022-07-20
KLECKNER JOHN
SOLD
-2,496.08
56.729
-44
Principal Accounting Officer
2022-06-30
PERFALL A CLAYTON
ACQUIRED
-
-
432
-
2022-06-30
Lalor Angela S
ACQUIRED
-
-
319
-
2022-06-30
Wienbar Sharon L
ACQUIRED
-
-
410
-
2022-06-07
Bodem Barbara W.
ACQUIRED
-
-
2,044
-
2022-06-07
Ortiz Christine
ACQUIRED
-
-
2,044
-

1–10 of 20

Matthew L. Trerotola
16200
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.

ENOV Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Oct. 01, 2021
Sep. 30, 2022
Oct. 01, 2021
Income Statement [Abstract]    
Net sales$ 383,814$ 359,923$ 1,154,388$ 1,027,130
Cost of sales167,990162,047516,758457,379
Gross profit215,824197,876637,630569,751
Selling, general and administrative expense182,187168,270564,324487,220
Research and development expense15,59912,45846,10233,860
Amortization of acquired intangibles31,99331,02594,60388,067
Insurance settlement (gain) loss9750(32,059)0
Restructuring and other charges2,9892,2307,6535,193
Operating loss (GAAP)(17,919)(16,107)(42,993)(44,589)
Interest expense, net6,3344,12217,94422,751
Debt extinguishment charges0020,10429,870
Unrealized (gain) loss on investment in ESAB Corporation63,1250(72,412)0
Realized gain on cost basis investment(8,800)0(8,800)0
Other income(300)0(300)0
Income (loss) from continuing operations before income taxes(78,278)(20,229)471(97,210)
Income tax benefit(12,329)(6,651)(16,176)(9,651)
Net income (loss) from continuing operations(65,949)(13,578)16,647(87,559)
Income (loss) from discontinued operations, net of taxes(527)40,43510,163164,358
Net income (loss)(66,476)26,85726,81076,799
Less: net income attributable to noncontrolling interest from continuing operations - net of taxes136191533836
Less: net income attributable to noncontrolling interest from discontinued operations - net of taxes08189662,399
Net income (loss) attributable to Enovis Corporation$ (66,612)$ 25,848$ 25,311$ 73,564
Net income (loss) per share - basic    
Net income per share, continuing operations, basic (in usd per share)$ (1.22)$ (0.26)$ 0.30$ (1.76)
Net income (loss) per share, discontinued operations, basic (in usd per share)(0.01)0.750.173.22
Net income (loss) per share, consolidated, basic (in usd per share)(1.23)0.490.471.46
Net income (loss) per share - diluted    
Net income (loss) per share, continuing operations, diluted (in usd per share)(1.22)(0.26)0.30(1.76)
Net income (loss) per share, discontinued operations, diluted (in usd per share)(0.01)0.750.173.22
Net income (loss) per share, consolidated operations, (in usd per share)$ (1.23)$ 0.49$ 0.46$ 1.46

ENOV Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
ASSETS  
Cash and cash equivalents$ 54,957$ 680,252
Trade receivable, less allowance for credit losses258,823254,958
Inventories, net416,872356,233
Prepaid expenses28,99226,046
Other current assets48,29329,176
Investment in ESAB Corporation200,2740
Total current assets associated with discontinued operations0956,614
Total current assets1,008,2112,303,279
Property, plant and equipment, net225,176235,113
Goodwill1,959,7951,934,258
Intangible assets, net1,116,5391,154,028
Lease asset - right of use67,08476,485
Other assets68,01374,700
Total non-current assets associated with discontinued operations02,738,049
Total assets4,444,8188,515,912
LIABILITIES AND EQUITY  
Current portion of long-term debt449,2237,701
Accounts payable179,672155,208
Accrued liabilities225,021225,391
Total current liabilities associated with discontinued operations0635,284
Total current liabilities853,9161,023,584
Long-term debt, less current portion02,078,625
Non-current lease liability52,03256,549
Other liabilities130,668122,159
Total non-current liabilities associated with discontinued operations0573,562
Total liabilities1,036,6163,854,479
Equity:  
Common stock, $0.001 par value; 133,333,333 shares authorized; 54,148,315 and 52,083,078 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively5452
Additional paid-in capital2,908,9134,544,315
Retained earnings614,335589,024
Accumulated other comprehensive loss(116,611)(516,013)
Total Enovis Corporation equity3,406,6914,617,378
Noncontrolling interest1,51144,055
Total equity3,408,2024,661,433
Total liabilities and equity$ 4,444,818$ 8,515,912